Upon targeting of the SMARCA5 gene in AML cell lines with a CRISPR/Cas9-mediated deletion strategy, we could observe that AML cells lacking SMARCA5 markedly slowed the proliferation rate and became dysplastic with multiple karyotypic abnormalities. This evidence concerns the gene SMARCA5 and acute myeloid leukemia.